What is Cidara Therapeutics Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cidara Therapeutics's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cidara Therapeutics's Operating Income for the
three
months ended in Mar. 2024 was $ -10.69 Mil. Cidara Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
GuruFocus does not calculate Cidara Therapeutics's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Cidara Therapeutics Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cidara Therapeutics (NAS:CDTX) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Cidara Therapeutics's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-10.69 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $3.18 Mil.
Cidara Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| GuruFocus does not calculate Cidara Therapeutics's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Cidara Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.
Cidara Therapeutics (Cidara Therapeutics) Business Description
Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Executives
| Leslie Tari |
officer: Chief Scientific Officer |
C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121 |
| Taylor Sandison |
officer: Chief Medical Officer |
6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
| Jeffrey Stein |
director, officer: President & CEO |
6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
| Shane Ward |
officer: CHIEF LEGAL OFFICER |
C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025 |
| Preetam Shah |
officer: CFO & CBO |
C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019 |
| Paul Daruwala |
officer: Chief Medical Officer |
6310 NANCY RIDGE DR, SAN DIEGO CA 92121 |
| Brady Johnson |
officer: Dir. of Finance & Controller |
6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121 |
| Timothy R Franson |
director |
320 WAKARA WAY, SALT LAKE CITY UT 84108 |
| Carin Canale-theakston |
director |
C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121 |
| Bonnie L Bassler |
director |
REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591 |
| James E. Levine |
officer: Chief Financial Officer |
55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
| Theodore R Schroeder |
director |
12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130 |
| Chrysa Mineo |
director |
10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
| David L Gollaher |
director |
6310 NANCY RIDGE DR, SAN DIEGO CA 92121 |
| Daniel D Burgess |
director |
C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121 |
Cidara Therapeutics (Cidara Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CDTX has been successfully added to your 